Klacid Hp

Per Klacid Hp (7 days) combi pack 14 Klacid tab each containing Clarithromycin 500 mg, 14 Controloc tab each containing Pantoprazole Na 40 mg, 14 Ospamox tab each containing Amoxicillin 1 g. Per Klacid Hp (14 days) combi pack 28 Klacid tab each containing Clarithromycin 500 mg, 28 Controloc tab each containing Pantoprazole Na 40 mg, 28 Ospamox tab each containing Amoxicillin 1 g

PUD associated w/ H pylori.

1 tab of each drug bd for 1-2 wk.

Controloc: Should be taken on an empty stomach: Take 1 hr before meals. Swallow whole, do not chew/crush. Klacid & Ospamox: May be taken with or without food.

Klacid: Hypersensitivity to macrolides. Not to be given to patients w/ history of congenital or documented acquired QT prolongation or ventricular cardiac arrhythmia including Torsade de pointes; hypokalemia. Concomitant use w/ astemizole, cisapride, domperidone, pimozide, terfenadine, ergot alkaloids, oral midazolam, HMG-CoA reductase inhibitors, colchicine, ticagrelor, ranolazine. Not to be used in severe hepatic failure w/ renal impairment. Controloc: Hypersensitivity. Not to be used in combination treatment for H pylori eradication in patients w/ moderate to severe hepatic or renal dysfunction. Ospamox: Hypersensitivity to penicillins, cephalosporins. Not to be given to patients w/ mononucleosis & lymphatic leukemia; severe GI infections w/ persistent diarrhea or vomiting. Patients w/ allergic diatheses or bronchial asthma & hay fever.

Discontinue use if severe acute hypersensitivity reactions or cutaneous ARs, including erythema multiforme, SJS, TEN, DRESS, acute generalized exanthematous pustulosis (AGEP) occurs. Pregnancy & lactation. Klacid: Superinfection may occur w/ long-term use. Patients w/ CV events, pneumonia, mild to moderate skin & soft tissue infections. Concomitant use w/ colchicine, HMG-CoA reductase inhibitors (statins), oral hypoglycemic agents/insulin & anticoagulants. Hepatic & moderate to severe renal impairment. Controloc: Exclude gastric malignancy prior to treatment. Discontinue use 5 days prior to chromogranin A measurements. Ospamox: Antibiotic-induced pseudomembranous colitis. Maintain adequate fluid intake & urine output during treatment. Concomitant use w/ antiperistaltic drugs.

Headache, diarrhea. Klacid: Dyspepsia, vomiting, taste perversion; oral monilia. Controloc: Constipation, flatulence, peripheral edema, fever, depression, myalgia (upon discontinuation); erythema multiforme, subacute cutaneous erythematosus. Ospamox: Fatigue, fever, joint pain, angioneurotic edema, interstitial nephritis. Klacid & Controloc: Abdominal pain; allergic reactions, severe cutaneous ARs eg, AGEP, SJS, TEN, DRESS. Klacid & Ospamox: Nausea; stomatitis, glossitis.

Klacid: Potential severe drug interaction effects w/ cisapride, domperidone, pimozide, astemizole, terfenadine, ergot alkaloid, oral midazolam, HMG-CoA reductase inhibitors. Concomitant use w/ efavirenz, nevirapine, rifampicin, rifabutin, rifapentine, etravinine, fluconazole, ritonavir; antiarrhythmics, oral hypoglycemic agents/insulin, CYP3A-based interactions, omeprazole, sildenafil, tadalafil, vardenafil, theophylline, carbamazepine, tolterodine, triazolobenzodiazepines eg, alprazolam, midazolam, triazolam; colchicine, digoxin, zidovudine, phenytoin, valproate; atazanavir, Ca-channel blockers, itraconazole, saquinavir. Controloc: Reduced absorption w/ pH-dependent drugs eg, ketoconazole. Ospamox: May promote skin rashes w/ allopurinol. Not to be combined w/ bacteriostatic antibiotics eg, tetracyclines, chloramphenicol. Reduced tissue distribution & diffusion by probenecid. Reduced efficacy of OCs. Reduced absorption by antacid. False +ve non-enzymatic urinary glucose test result. Impaired urobilinogen tests.

Antacids, Antireflux Agents & Antiulcerants

A02BD04 - pantoprazole, amoxicillin and clarithromycin ; Belongs to the class of various combinations for the eradication of Helicobacter pylori infection. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).

B